

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/425, C07D 277/58	A1	(11) International Publication Number: ☒ WO 98/50035 (43) International Publication Date: 12 November 1998 (12.11.98)
(21) International Application Number: ☒ PCT/US98/09229 (22) International Filing Date: ☒ 6 May 1998 (06.05.98) (30) Priority Data: 08/852,447 7 May 1997 (07.05.97) ☒ US 08/887,810 3 July 1997 (03.07.97) ☒ US 08/887,809 3 July 1997 (03.07.97) ☒ US (71) Applicant: ROMARK LABORATORIES, L.C. [US/US]; Suite 870, 6200 Courtney Campbell Causeway, Tampa, FL 33607 (US). (72) Inventor: ROSSIGNOL, Jean-François; 2650 Heron Lane S, Clearwater, FL 34622 (US). (74) Agents: PENDORF, Stephan, A. et al.; Pendorf & Cutliff, P.O. Box 20445, Tampa, FL 33622-0445 (US).	(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, <u>SG</u> , SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	

(54) Title: PHARMACEUTICAL COMPOSITIONS OF TIZOXANIDE AND NITAZOXANIDE

(57) Abstract

A pharmaceutical composition containing as active agent at least one compound selected among the group consisting of formula (I) and formula (II). The active agent is preferably in the form of particles having a particle size smaller than 200 μm and a mean particle size of greater than 10 μm . The pharmaceutical compositions are preferably stabilized with at least one pharmaceutically acceptable acid. The pharmaceutical compositions are particularly useful for treatment of opportunistic infections in persons with compromised or suppressed immune systems, and in treatment of infections of trematodes.

